Search
Tirapazamine
go.drugbank.com/drugs/DB04858InvestigationalThis activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1,2,4-benzotriazin-3-amine, 1,4-dioxide, 3-Amino-1,2,4-benzotriazine 1,4-dioxideOmacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnOmacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies
Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds with 4 or More RingsSynonyms: 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULASOsanetant
go.drugbank.com/drugs/DB04872InvestigationalIn a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.
Categories: Heterocyclic Compounds, 1-RingVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea … Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme.
Mixtures: JALRA ®M 50 MG /500 MG, JALRA® M 50 MG / 850 MGCategories: Glucagon-Like Peptide 1, P-glycoprotein substratesVoglibose
go.drugbank.com/drugs/DB04878InvestigationalVoglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
Vatalanib
go.drugbank.com/drugs/DB04879InvestigationalVatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.
Categories: Heterocyclic Compounds, 1-RingCilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBrecanavir
go.drugbank.com/drugs/DB04887InvestigationalIn December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring